Bank of New York Mellon
ABMD

Bank of New York Mellon’s Abiomed Inc ABMD Stock Holding History

Bank of New York Mellon’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-629,095
Closed -$155M – 4594
2022
Q3 		$155M Sell
629,095
-17,011
-3% -$4.59M 0.04% 434
2022
Q2 		$160M Buy
646,106
+9,394
+1% +$2.54M 0.04% 431
2022
Q1 		$211M Sell
636,712
-16,080
-2% -$4.95M 0.04% 391
2021
Q4 		$234M Sell
652,792
-15,742
-2% -$5.32M 0.04% 382
2021
Q3 		$218M Sell
668,534
-21,073
-3% -$7.14M 0.04% 385
2021
Q2 		$215M Buy
689,607
+2,632
+0.4% +$807K 0.04% 380
2021
Q1 		$219M Buy
686,975
+33,095
+5% +$10.6M 0.04% 367
2020
Q4 		$212M Buy
653,880
+10,295
+2% +$2.85M 0.05% 354
2020
Q3 		$178M Buy
643,585
+23,342
+4% +$6.72M 0.04% 374
2020
Q2 		$150M Buy
620,243
+36,797
+6% +$7.39M 0.04% 399
2020
Q1 		$84.7M Sell
583,446
-26,466
-4% -$4.39M 0.03% 530
2019
Q4 		$104M Sell
609,912
-90,084
-13% -$16.7M 0.03% 588
2019
Q3 		$125M Buy
699,996
+30,281
+5% +$6.55M 0.03% 475
2019
Q2 		$174M Buy
669,715
+119,783
+22% +$31.8M 0.05% 360
2019
Q1 		$157M Buy
549,932
+56,709
+11% +$18.8M 0.04% 394
2018
Q4 		$160M Sell
493,223
-109,198
-18% -$37.9M 0.05% 353
2018
Q3 		$271M Sell
602,421
-33,869
-5% -$13.4M 0.07% 266
2018
Q2 		$260M Sell
636,290
-207,968
-25% -$75.3M 0.07% 273
2018
Q1 		$246M Buy
844,258
+162,251
+24% +$41.1M 0.07% 292
2017
Q4 		$128M Sell
682,007
-27,195
-4% -$5.08M 0.03% 510
2017
Q3 		$120M Sell
709,202
-31,374
-4% -$4.74M 0.03% 521
2017
Q2 		$106M Buy
740,576
+17,148
+2% +$2.3M 0.03% 553
2017
Q1 		$90.6M Sell
723,428
-10,518
-1% -$1.22M 0.03% 626
2016
Q4 		$82.7M Buy
733,946
+185,894
+34% +$21.5M 0.02% 645
2016
Q3 		$70.5M Buy
548,052
+49,638
+10% +$5.95M 0.02% 695
2016
Q2 		$54.5M Sell
498,414
-18,974
-4% -$1.89M 0.02% 808
2016
Q1 		$49.1M Sell
517,388
-219,605
-30% -$18.5M 0.01% 873
2015
Q4 		$66.5M Buy
736,993
+10,879
+1% +$923K 0.02% 721
2015
Q3 		$67.4M Buy
726,114
+59,036
+9% +$5.2M 0.02% 701
2015
Q2 		$43.8M Buy
667,078
+50,595
+8% +$3.36M 0.01% 979
2015
Q1 		$44.1M Buy
616,483
+186,201
+43% +$10.1M 0.01% 972
2014
Q4 		$16.4M Buy
430,282
+28,008
+7% +$883K ﹤0.01% 1608
2014
Q3 		$9.99M Sell
402,274
-4,166
-1% -$106K ﹤0.01% 1897
2014
Q2 		$10.2M Sell
406,440
-45,343
-10% -$1.06M ﹤0.01% 1919
2014
Q1 		$11.8M Sell
451,783
-4,216
-0.9% -$117K ﹤0.01% 1802
2013
Q4 		$12.2M Buy
455,999
+66,780
+17% +$1.65M ﹤0.01% 1761
2013
Q3 		$7.42M Buy
389,219
+54,965
+16% +$1.26M ﹤0.01% 1992
2013
Q2 		$7.21M Buy
+334,254
New +$6.72M ﹤0.01% 1973

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bank of New York Mellon's ABMD Position: Q4 2022 in Review

Bank of New York Mellon sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 629,095 shares — an estimated $155M sold.

Bank of New York Mellon first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $271M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Bank of New York Mellon reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 629,095 Abiomed Inc shares in Q4 2022, an estimated $155M.
  • Bank of New York Mellon first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Bank of New York Mellon's Abiomed Inc position peaked at $271M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.